GLSI · NASDAQ · Biotechnology

Greenwich LifeSciences (GLSI)

Runs a single Phase III trial for a peptide vaccine preventing HER2-positive breast cancer recurrence.

$17.51
After hours−0.02 (−0.11%)
At close$17.53(−10.01%)